- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01999881
Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients
Panoramica dello studio
Stato
Condizioni
- Stadio IIIA Carcinoma polmonare non a piccole cellule
- Stadio IIIB Carcinoma polmonare non a piccole cellule
- Carcinoma polmonare a piccole cellule in stadio esteso
- Carcinoma polmonare a piccole cellule ricorrente
- Carcinoma polmonare non a piccole cellule ricorrente
- Carcinoma polmonare non a piccole cellule in stadio IV
- Sano, nessuna evidenza di malattia
- Cancro polmonare a piccole cellule in stadio limitato
- Stadio IA Carcinoma polmonare non a piccole cellule
- Stadio IB Carcinoma polmonare non a piccole cellule
- Stadio IIA Carcinoma polmonare non a piccole cellule
- Carcinoma polmonare non a piccole cellule in stadio IIB
Descrizione dettagliata
PRIMARY OBJECTIVES:
I. Determine the effect of an eight-week exercise intervention on biomarkers of inflammation, oxidative stress, exercise capacity, and quality of life in lung cancer patients.
SECONDARY OBJECTIVES:
I. Determine the effect of an eight-week exercise intervention on markers of stress and quality of life in the support person of lung cancer patients.
OUTLINE: Participants are randomized to 1 of 2 arms.
ARM A: Patients and their support persons undergo a supervised combined aerobic exercise comprising walking, cycling, or video-based aerobics and strength training using resistance bands for 40 minutes 2 days a week at the University of Wisconsin Hospital and Clinic (UWHC) and 3 days a week at home over 8 weeks.
ARM B: Patients and their support persons undergo the usual care over 8 weeks.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Wisconsin
-
Madison, Wisconsin, Stati Uniti, 53715
- UW Health Oncology - 1 South Park
-
Madison, Wisconsin, Stati Uniti, 53792
- University of Wisconsin, Madison
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- LUNG CANCER PATIENTS: A confirmed diagnosis of any stage lung cancer (non-small cell lung cancer [NSCLC] or small cell lung cancer [SCLC])
- LUNG CANCER PATIENTS: Can be receiving any type of treatment (chemotherapy, radiation therapy, both or neither) are eligible
- LUNG CANCER PATIENTS: Able to understand and read in English sufficiently to adequately complete informed consent to participate and to complete the questionnaires
- LUNG CANCER PATIENTS: For patients treated with curative intent, and who have not relapsed, they must be within 1 year of their diagnosis of lung cancer (determined by date of diagnostic pathology sample)
- SUPPORT PERSONS: Able to understand and read in English sufficiently to adequately complete informed consent to participate and to complete the questionnaires
Exclusion Criteria:
- LUNG CANCER PATIENTS: Symptomatic heart disease including congestive heart failure or arrhythmia
- LUNG CANCER PATIENTS: Documented myocardial infarction in the last three months
- LUNG CANCER PATIENTS: Central nervous system (CNS) metastases that results in impaired ability to participate in an exercise program at the discretion of the study physician
- LUNG CANCER PATIENTS: Any psychological or physical disease that would impair or prevent participation in an exercise program at the discretion of the study physician
- LUNG CANCER PATIENTS: Cognitive or reading impairments that would preclude them from completing questionnaires
- LUNG CANCER PATIENTS: Current participation in an exercise program
- SUPPORT PERSONS: Symptomatic heart disease including congestive heart failure or arrhythmia
- SUPPORT PERSONS: Documented myocardial infarction in the last three months
- SUPPORT PERSONS: Cognitive or reading impairments that would preclude them from completing questionnaires
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Terapia di supporto
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Arm A (aerobic and exercise training)
Patients and their support persons undergo a supervised combined aerobic exercise comprising walking, cycling, or video-based aerobics and strength training using resistance bands for 40 minutes 2 days a week at the UWHC and 3 days a week at home over 8 weeks.
|
Studi correlati
Studi accessori
Altri nomi:
Receive aerobic and exercise intervention
|
|
Comparatore attivo: Arm II (usual care)
Patients and their support persons undergo the usual care over 8 weeks.
|
Studi correlati
Studi accessori
Altri nomi:
Receive usual care
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in biomarkers of inflammation
Lasso di tempo: Baseline up to 8 weeks
|
Descriptive statistics will be calculated and compared between the two treatment groups at baseline using unpaired t-tests and Chi-Square analyses.
A two-way analysis of variance will be used to examine the effects of the treatment over time.
|
Baseline up to 8 weeks
|
|
Change in oxidative damage as indicated by serum 8-hydroxydeoxyguanosine (8-oh-dG)
Lasso di tempo: Baseline up to 8 weeks
|
Descriptive statistics will be calculated and compared between the two treatment groups at baseline using unpaired t-tests and Chi-Square analyses.
A two-way analysis of variance will be used to examine the effects of the treatment over time.
|
Baseline up to 8 weeks
|
|
Change in time to walk 400 m
Lasso di tempo: Baseline up to 8 weeks
|
Descriptive statistics will be calculated and compared between the two treatment groups at baseline using unpaired t-tests and Chi-Square analyses.
A two-way analysis of variance will be used to examine the effects of the treatment over time.
|
Baseline up to 8 weeks
|
|
Change in physical well-being scores on the Functional Assessment of Cancer Therapy-Lung (FACT-L)
Lasso di tempo: Baseline up to 8 weeks
|
Descriptive statistics will be calculated and compared between the two treatment groups at baseline using unpaired t-tests and Chi-Square analyses.
A two-way analysis of variance will be used to examine the effects of the treatment over time.
|
Baseline up to 8 weeks
|
|
Change in functional well-being scores on the FACT-L
Lasso di tempo: Baseline up to 8 weeks
|
Descriptive statistics will be calculated and compared between the two treatment groups at baseline using unpaired t-tests and Chi-Square analyses.
A two-way analysis of variance will be used to examine the effects of the treatment over time.
|
Baseline up to 8 weeks
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in stress scores on the SF-36
Lasso di tempo: Baseline up to 8 weeks
|
Descriptive statistics will be calculated and compared between the two treatment groups at baseline using unpaired t-tests and Chi-Square analyses.
A two-way analysis of variance will be used to examine the effects of the treatment over time.
|
Baseline up to 8 weeks
|
|
Change in quality-of-life scores on the SF-36
Lasso di tempo: Baseline up to 8 weeks
|
Descriptive statistics will be calculated and compared between the two treatment groups at baseline using unpaired t-tests and Chi-Square analyses.
A two-way analysis of variance will be used to examine the effects of the treatment over time.
|
Baseline up to 8 weeks
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Toby Campbell, University of Wisconsin, Madison
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Processi patologici
- Malattie delle vie respiratorie
- Neoplasie
- Malattie polmonari
- Neoplasie per sede
- Attributi della malattia
- Neoplasie delle vie respiratorie
- Neoplasie toraciche
- Carcinoma, broncogeno
- Neoplasie bronchiali
- Neoplasie polmonari
- Carcinoma, polmone non a piccole cellule
- Ricorrenza
- Carcinoma polmonare a piccole cellule
Altri numeri di identificazione dello studio
- UW13034 (Altro identificatore: University of Wisconsin Carbone Cancer Center)
- P30CA014520 (Sovvenzione/contratto NIH degli Stati Uniti)
- A534260 (Altro identificatore: UW Madison)
- SMPH\MEDICINE\HEM-ONC (Altro identificatore: UW Madison)
- 2013-0752 (Institutional Review Board)
- NCI-2013-02185 (Identificatore di registro: NCI Trial ID)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .